読み込み中
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
通常取引
$9.175
+$0.1867 · +2.08%
日中の時刻はETです。市場データは遅延する場合があります。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日中レンジ
現在 $9.175
52週レンジ
現在 $9.175
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
58
まちまち
リスク
50
やや高いリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
日中レンジ
現在 $9.175
52週レンジ
現在 $9.175
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 34.2万 USD | 11.8万 USD | 4000 USD | 5000 USD | 6000 USD |
| 粗利益 | −34.2万 USD | −11.8万 USD | −4000 USD | −5000 USD | −6000 USD |
| 研究開発 | 213.3万 USD | 53.4万 USD | 33.2万 USD | 34.7万 USD | 24.5万 USD |
| 販売・一般管理 | 377.4万 USD | 76.8万 USD | 30.3万 USD | 54.8万 USD | 45.2万 USD |
| 営業費用 | 590.7万 USD | 130.2万 USD | 63.5万 USD | 89.5万 USD | 69.7万 USD |
| 受取利息 | 37万 USD | — | — | — | — |
| 支払利息 | 314.3万 USD | 3000 USD | 2000 USD | 2000 USD | 2000 USD |
| 減価償却費と償却費 | 34.2万 USD | 11.8万 USD | 4000 USD | 5000 USD | 6000 USD |
| 営業利益 | −624.9万 USD | −130.2万 USD | −63.5万 USD | −89.5万 USD | −70.3万 USD |
| 純利益 | −333.5万 USD | −154.5万 USD | −60万 USD | −77.9万 USD | −71.1万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
